Back to results

A Safety Study of PTI-125 in Healthy Volunteers

Primary Purpose

Alzheimer Disease, Early Onset, Alzheimer Disease

Status

Completed

Phase

Phase 1

Locations

United States

Study Type

Interventional

Intervention

50 mg PTI-125

100 mg PTI-125

200 mg PTI-125

About this trial

This is an interventional prevention trial for Alzheimer Disease, Early Onset

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Male or female subjects between 18 and 45 years of age, inclusive.
The subject has a body mass index (BMI) within 18-30 kg/m2 (inclusive).
The subject is in good health as determined by medical history and physical examination and clinical laboratory parameters.
The subject is willing and able to speak, read, and understand English and provide written informed consent.
The subject is a non-smoker for at least 12 months. If a former smoker, the reason for stopping must be evaluated.
Females who are physically incapable of childbearing defined as postmenopausal, or surgically sterile (hysterectomy, bilateral tubal ligation, bilateral oophorectomy or an Essure procedure). Appropriate documentation (ex; medical record) of the surgical sterilization procedure to be obtained and held within the subject's study file.
The subject must agree to comply with the drawing of blood samples for the PK assessments.
The subject is willing and able to comply with all testing and requirements defined in the protocol.
The subject is willing and able to remain at the study site unit for the duration of the confinement period and return for the outpatient visit.

Exclusion Criteria:

The subject has any relevant deviations from normal in physical examination, electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the investigator.
The subject has had a clinically significant illness within 30 days of Check-in.
The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.
The subject has used any prescription medication within 14 days of dosing or overthe- counter (OTC) medication within 48 h of dosing or intends to use any prescription medication or OTC medication during the study that may interfere with the evaluation of study medication.
The subject has used alcohol, caffeine or xanthine-containing products 48 h before dosing or intends to use any of these products during the study.
The subject has used grapefruit, grapefruit juice, or grapefruit-containing products days before dosing or intends to use any of these products during the study.
The subject has a history of substance abuse or a positive ethanol breath test, urine cotinine, or urine drug screen at screening or at check-in. The subject has a positive serum hepatitis B surface antigen or positive HCV antibody test at the Screening Visit.
The subject has a positive HIV test at the Screening Visit.
Female subject is pregnant or breastfeeding.
The subject has received an investigational drug within 30 days of Check-in.
The subject has donated or lost a significant volume of blood (>450 mL) within 4 weeks prior to the study.
The subject is unwilling to reside in the study unit for the duration of the study or to cooperate fully with the investigator or site personnel.
The subject has an AST/ALT or total bilirubin greater than the ULN. One repeat test will be allowed.

Sites / Locations

Worldwide Clinical Trials

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Active Comparator

Placebo Comparator

Active Comparator

Placebo Comparator

Active Comparator

Placebo Comparator

Arm Label

50 mg PTI-125

50 mg PTI-125 Placebo

100 mg PTI-125

100 mg PTI-125 Placebo

200 mg PTI-125

200 mg PTI-125 Placebo

Arm Description

Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.

Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.

Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.

Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.

Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.

Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.

Outcomes

Primary Outcome Measures

Maximum Plasma Concentration (Cmax)

The peak drug concentration will be obtained directly from the data without interpolation.

Time to Maximum Plasma Concentration (Tmax) (Tmax)

The time to peak drug concentration will be obtained directly from the data without interpolation

Time to Last Quantifiable Plasma Concentration (Tlast)

The time to the last quantifiable drug concentration will be obtained directly from the data without interpolation.

Last Quantifiable Plasma Concentration (Clast)

The concentration of the last quantifiable drug will be obtained directly from the data without interpolation concentration

Elimination Rate Constant (λz)

The elimination rate constant (λz) will be calculated.

Termination Elimination Half-Life (T1/2)

The terminal elimination half-life (T1/2) will be calculated.

Area Under the Curve (AUC)

The AUC from time zero to the time of the last quantifiable concentration (AUClast) will be calculated.

Area Under the Curve to Infinity (AUCinf)

The AUC from time zero extrapolated to infinity (AUCinf) will be calculate.

Percent Extrapolated of Area Under the Curve to Infinity (AUCextrap[%]).

The percentage of AUCinf based on extrapolation (AUCextrap[%]).

Oral Clearance (Cl/F)

The apparent oral clearance will be calculated.

Volume of Distribution (Vz/F)

Vz/F, apparent volume of distribution will be calculated.

Secondary Outcome Measures

Full Information

NCT ID

NCT03784300

First Posted

December 18, 2018

Last Updated

May 7, 2021

Sponsor

Pain Therapeutics

Collaborators

National Institute on Aging (NIA)

1. Study Identification

Unique Protocol Identification Number

NCT03784300

Brief Title

A Safety Study of PTI-125 in Healthy Volunteers

Official Title

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers

Study Type

Interventional

2. Study Status

Record Verification Date

May 2021

Overall Recruitment Status

Completed

Study Start Date

August 18, 2017 (Actual)

Primary Completion Date

October 9, 2017 (Actual)

Study Completion Date

March 27, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Pain Therapeutics

Collaborators

National Institute on Aging (NIA)

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers

Detailed Description

This was a Phase I, single center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study in healthy volunteers, 18 to 45 years of age. A total of twenty-four (24) subjects were enrolled into the study in one of three dose cohorts. Each cohort contained eight subjects; six subjects received PTI-125 and two received placebo. Three doses of PTI-125 oral solution (50, 100, and 200 mg) or placebo solution were administered to respective cohorts. The study included a screening period (Day -28 to Day -1), an inpatient treatment period (Day 0 through Day 4), and a follow-up visit (Day 7). Subjects reported to the clinic on the day before dosing and were randomized to receive either a single dose of orally administered PTI-125 or placebo. Each dose was administered following an overnight fast of at least 10 hours. For each dose level, dosing was staggered such that two subjects (one active and one placebo) were dosed prior to the rest of the group. After a minimum of 24 hours and review of all 24-hour safety assessments (electrocardiogram [ECG], a brief physical examination, vital signs, and laboratory assessments) an independent Data Safety Monitoring Board/Data Monitoring Committee (DSMB/DMC) determined whether the remaining 6 subjects were to be dosed. Pharmacokinetic blood samples were obtained prior to dosing and at specified intervals during the study (0-72 hours post-dose). Blood draws for laboratory testing were performed prior to dosing and at 24 hours post dose. After safety assessments of ECG, vital signs, and a brief physical exam at 72 hours, subjects were discharged from the clinic and returned 7 days post-dose for a final safety assessment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Alzheimer Disease, Early Onset, Alzheimer Disease

7. Study Design

Primary Purpose

Prevention

Study Phase

Phase 1

Interventional Study Model

Parallel Assignment

Model Description

Single center, randomized, double-blind, placebo controlled, SAD study of three escalating doses of PTI-125. A total of 24 healthy subjects enrolled in one of three dose cohorts. Each cohort will contain 8 subjects; six receive PTI-125 and two receive placebo. Three SAD does of PTI-125 oral solution (50, 100 or 200 mg) or placebo solution will be administered.

Masking

ParticipantInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

24 (Actual)

8. Arms, Groups, and Interventions

Arm Title

50 mg PTI-125

Arm Type

Active Comparator

Arm Description

Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.

Arm Title

50 mg PTI-125 Placebo

Arm Type

Placebo Comparator

Arm Description

Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.

Arm Title

100 mg PTI-125

Arm Type

Active Comparator

Arm Description

Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.

Arm Title

100 mg PTI-125 Placebo

Arm Type

Placebo Comparator

Arm Description

Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.

Arm Title

200 mg PTI-125

Arm Type

Active Comparator

Arm Description

Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.

Arm Title

200 mg PTI-125 Placebo

Arm Type

Placebo Comparator

Arm Description

Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.

Intervention Type

Drug

Intervention Name(s)

50 mg PTI-125

Intervention Description

PTI-125 50 mg Oral Solution

Intervention Type

Drug

Intervention Name(s)

100 mg PTI-125

Intervention Description

PTI-125 100 mg Oral Solution

Intervention Type

Drug

Intervention Name(s)

200 mg PTI-125

Intervention Description

PTI-125 200 mg Oral Solution

Primary Outcome Measure Information:

Title

Maximum Plasma Concentration (Cmax)

Description

The peak drug concentration will be obtained directly from the data without interpolation.

Time Frame